Stroke. 1997;28:1351-1356
(Stroke. 1997;28:1351-1356.)
© 1997 American Heart Association, Inc.
Impaired Calcium Regulation in Subcortical Vascular Encephalopathy
Anne Eckert, PhD;
Manfred Oster, MD;
Hans Förstl, MD;
Michael Hennerici, MD;
Walter E. Müller, PhD
From the Departments of Psychopharmacology (A.E., W.E.M.) and Psychiatry
(H.F.), Central Institute of Mental Health, and the Department of Neurology
(M.O., M.H.), Klinikum Mannheim of the University of Heidelberg, Mannheim,
Germany.
Correspondence to Prof Dr Walter E. Müller, Department of Pharmacology, University of Frankfurt, Biocenter, Geb N260, D-60439 Frankfurt, Germany. E-mail psymail{at}as200.zimannheim.de
 |
Abstract
|
|---|
Background and Purpose A number of clinical
observations and
first in vitro findings indicate that chronic cerebral
ischemia
influences immunologic status, such as the
proliferative response
of T lymphocytes. The purpose of the present
report was to assess
(1) whether changes of immune function are
likewise detectable
in patients with progressive subcortical vascular
encephalopathy
(SVE) by investigating the
[Ca
2+]
i homeostasis of lymphocytes
and (2)
whether differences exist in calcium regulation between
lymphocytes
from SVE patients and from Alzheimer's disease (AD)
patients.
This is of great interest, since specific changes
have been reported
recently in AD patients.
Methods [Ca2+]i was recorded
in 26 patients with SVE, 26 age-matched nondemented control subjects,
and 26 age-matched patients with AD. Basal
[Ca2+]i and [Ca2+]i
after lymphocyte activation with the mitogen phytohemagglutinin (PHA)
were measured with the fura 2 method. In addition, modulation of the
Ca2+ signaling by the peptide ß-amyloid and the potassium
channel blocker tetraethylammonium was
studied.
Results Basal [Ca2+]i was not
different between patients and control subjects. After stimulation with
PHA, however, a significant reduction of the Ca2+ response
could be observed in lymphocytes of SVE patients compared with control
subjects and with AD patients, providing evidence that the
Ca2+ homeostasis of lymphocytes is impaired in SVE. The
effect of the peptide ß-amyloid, the major constituent of senile
plaques in AD brain, on Ca2+ signaling was similar in SVE
patients and nondemented control subjects but typically reduced in
cells of AD patients. Potassium channels were not involved in the
impaired Ca2+ response of SVE lymphocytes after cell
activation.
Conclusions [Ca2+]i is not only
one of the most important second messengers in signal transduction of
many cells but also an early event in the signal cascade of cell
proliferation as a reaction to antigen recognition. This mechanism
seems to be impaired in SVE. These findings may result in new insights
regarding the pathogenesis of this disease and the possible involvement
of inflammatory or immunologic disturbances.
Key Words: calcium cerebrovascular disorders dementia lymphocytes encephalopathy
 |
Introduction
|
|---|
Vascular dementia is
the second most common cause of dementia
in the western world, after
AD.
1 2 3 4 Very little evidence
is available regarding
possible implications of immunologic
dysfunction in the pathogenesis of
this disease. Some early
findings in patients indicate that immunologic
status underlies
alterations during stroke. Thus, stroke seems to
trigger systemic
memory T cells.
5 In the early stages, the
proliferative responses
to the mitogens PHA or concanavalin A and to
tuberculin were
reduced in T lymphocytes from stroke patients compared
with
control subjects.
6 Furthermore, markers for systemic
leukocyte
activation, eg, proinflammatory cytokines, were
higher in plasma
7 and brains
8 of patients
with acute ischemic cerebrovascular
disease than in control
subjects. On the basis of these data,
it seems possible to speculate
that after several ischemic insults
during cerebrovascular
disease or vascular dementia, similar
or related alterations may be
present. Furthermore, it has been
emphasized that the immunologic
response plays an important
role in the pathogenesis of cerebral
vasospasm after subarachnoid
hemorrhage.
9
Even a lymphocyte infiltration in ischemic lesions
of the rat
cortex and an intensive accumulation of polymorphonuclear
lymphocytes
in the regions of cerebral infarction of patients with
ischemic
stroke have been reported.
10 11
Free [Ca2+]i is elevated by several second
messenger generating systems. Because of its broad and crucial role in
signal transduction pathways, [Ca2+]i has
attracted specific attention. In lymphocytes,
[Ca2+]i represents an early event in
the intracellular signal cascade of cell proliferation and
cytokine activation.12 Therefore, measurement of
[Ca2+]i appears to be a valuable tool to
detect early disturbances in the immunologic function of these
cells.
The goal of the present study was to assess specific changes of
[Ca2+]i regulation in a large group of
patients with SVE13 and to distinguish between SVE, AD,
and nondemented control subjects.
 |
Subjects and Methods
|
|---|
Subjects
The experiments were performed with the use of blood cells from
26
patients (14 men and 12 women) with SVE
13 14 15 following
the
diagnostic criteria for research studies
(NINDS-AIREN).
16 Patients
underwent a structured medical
and neurological examination
as well as neuropsychological interviews
following a research
protocol with particular emphasis on the presence
of motor and
gait disturbances, urinary incontinence, memory
and attention
disorders, frontal release signs, and spontaneous
episodes.
All patients recruited showed evidence of memory impairment
with
at least one deficit in cognitive domains (eg, abstract thinking,
language,
orientation, flexibility, personality changes) or isolated
functional
impairment unrelated to physical deficits. Furthermore,
dementia
was diagnosed only on the basis of combined information from
the
initial and follow-up studies. All patients who entered this
study
had repeated follow-ups, with confirmation of the entry
diagnosis for
at least a 2-year period. Several standardized
test procedures,
including the Structured Interview for the
Diagnosis of Dementia, Brief
Assessment Interview, and Nürnberg
Ageing Inventory, were used to
exclude patients with other psychopathological
diseases, in particular
a significant mood disorder and degenerative
dementia diseases.
Moreover, care was taken to avoid inclusion
of patients with mixed
forms of dementia by strict adherence
to the NINDS-AIREN and
NINCDS-ADRDA criteria.
16 17 Essential
differences
consisted of focal neurological findings, stepwise
versus progressive
decline of cognitive functions, presence
or absence of lacunar cortical
infarction, and white matter
lesions on MRI scans. The mean age was
72±6.2 years (range,
59 to 84 years; median, 71 years).
Blood cells from 26 patients (14 men and 12 women) with
"probable" or "possible" AD according to the NINCDS-ADRDA
criteria17 were used as a second demented group to
elucidate differences in pathogenesis. Patients were recruited from an
ongoing longitudinal study.18 These patients were also
followed for at least a 2-year period, and confirmation of the
diagnosis was established before entry into the present study. With
regard to the aforementioned criteria, particular care was taken to
separate vascular from degenerative dementia disorders and to exclude
patients with mixed diseases. The mean age was 68±8.6 years (range, 51
to 86 years; median, 68 years).
Blood cells from 26 nondemented individuals of similar age (mean age,
69±6.7 years; median, 70 years; range, 56 to 84 years; 14 men and 12
women) were used as controls. These subjects also underwent
standardized neurological and neuropsychological examinations, as
previously mentioned, and brain imaging disclosed cerebral infarction,
brain atrophy, or significant white matter lesions.
Approximately half of the AD patients, half of the aged control
subjects, and most of the SVE patients were taking
cardiovascular and antidiabetic drugs. Nine SVE
patients were taking calcium antagonists. None of the drugs
used are known to interfere with [Ca2+]i
homeostasis in lymphocytes. This is also the case for calcium
antagonists, since lymphocytes do not express L-type Ca2+
channels.19
Cell Separation
Peripheral blood lymphocytes were separated from
heparinized blood by centrifugation with Ficoll-Hypaque
at 400g for 40 minutes, as previously
described,20 according to the method of
Boyum.21
[Ca2+]i Measurements
Fura 2-AM (3 µmol/L) loading and measurements of
[Ca2+]i were performed as described
previously.22 Freshly prepared lymphocytes were stimulated
with PHA (Sigma) at a final concentration of 15 µg/mL.
[Ca2+]i was calculated according to the
method of Grynkiewicz et al.23 To investigate the
involvement of potassium channels in PHA-induced Ca2+
response, cells were exposed for 2 minutes to TEA (50 mmol/L)
before stimulation. To study the effects of preaggregated ßA25-35
(1 µmol/L; Sigma) on PHA-induced increases in
[Ca2+]i, freshly prepared lymphocytes were
preincubated with ßA25-35 for 60 seconds.20 22
Ca2+ responses to PHA in the presence or absence of
ßA25-35 are expressed as
Ca2+, which is the maximal
increase in [Ca2+]i over baseline.
Ca2+ßA25-35 is the ßA-induced increase in
[Ca2+]i over maximal stimulation by PHA.
Statistical Analysis
Significance was tested with ANOVA (SAS Institute), Student's
t test, or the paired t test.
 |
Results
|
|---|
Alterations of [Ca
2+]
i were investigated
in freshly prepared
peripheral lymphocytes of 26 SVE
patients, 26 age- and sex-matched
elderly nondemented control subjects,
and 26 AD patients (Table

).
Fig 1

shows
the time course of PHA-induced increase in
[Ca
2+]
i over baseline
[Ca
2+]
i (

Ca
2+) after PHA (15
µg/mL) stimulation
in lymphocytes from aged control subjects and SVE
patients.
The maximum Ca
2+ signal was reached after 1
minute in both groups
(Fig 1

). However, comparison of the time courses
revealed a
significantly impaired PHA-induced Ca
2+ response
in cells from
SVE patients compared with control subjects (ANOVA,
P=.002,
F=10.64; Fig 1

). The difference in
[Ca
2+]
i mobilization between
both groups was
mainly pronounced in the initial phase of the
Ca
2+ response
(ANOVA,
P<.001 for the time points within the
first 60
seconds), which is dominated by a Ca
2+ release from
intracellular
stores.
24 25

View larger version (18K):
[in this window]
[in a new window]
|
Figure 1. Time course of the increase in
[Ca2+]i ( Ca2+) in freshly
prepared lymphocytes from aged nondemented control subjects and SVE
patients after PHA (15 µg/mL) stimulation. Data are mean±SEM (n=26).
ANOVA indicates that the Ca2+ response in cells of SVE
patients was significantly reduced (P=.002, F=10.64). There
was also a significant interaction of diagnosis and time for PHA
stimulation (P=.0002, F=4.27).
|
|
In contrast, the PHA-induced Ca2+ increase was not
different between AD patients and control subjects (Fig 2
inset,
Table
), confirming previous findings.26 27 28 29
Moreover, measurement of basal [Ca2+]i in
lymphocytes revealed no difference among the three groups (Table
).
Approximately half of the AD patients and half of the aged control
subjects were taking drugs, mainly for cardiovascular
diseases, but none were taking calcium antagonists. For
each group, the basal [Ca2+]i and the
PHA-induced Ca2+ increase in lymphocytes of individuals on
drugs versus the drug-free individuals were not significantly different
(basal [Ca2+]i: control subjects, 107.7±19.4
versus 95.8±19.1 nmol/L; patients, 107.7±11.3 versus 99.0±18.6
nmol/L;
Ca2+: control subjects, 84.5±22.3 versus
102.8±15.7 nmol/L; patients, 106.7±27.1 versus 99.0±26.3 nmol/L,
respectively). The majority of the SVE patients were taking drugs for
cardiovascular diseases, and 9 of 26 patients were
taking calcium antagonists. There was no difference in
basal [Ca2+]i levels or in PHA-induced
Ca2+ increase between patients taking calcium
antagonists and calcium antagonistfree
individuals (basal [Ca2+]i: 97.2±12.0 versus
101.9±14.3 nmol/L;
Ca2+: 82.1±25.6 versus 83.7±25.1
nmol/L, respectively), which is in agreement with the report that
peripheral human lymphocytes do not express functional
voltage-gated L-type Ca2+ channels.19
Moreover, there was no significant difference in
Ca2+ to
PHA in lymphocytes of SVE patients with normotonus, mostly after
medication, compared with SVE patients with either hypotonus or
hypertonus. Furthermore, plasma cholesterol levels did not
differ among the three groups (Table
).
The time to reach the maximum Ca2+ peak after stimulation
with PHA was unaltered between SVE patients and age-matched control
subjects (control subjects: 68.1±26.6 seconds; SVE patients:
76.7±29.8 seconds) (Fig 3
). In contrast, the time to
reach the maximum Ca2+ peak was significantly delayed
(P<.01) in lymphocytes of AD patients compared with control
subjects (AD: 96.4±42.4 seconds; control subjects: 68.1±26.6 seconds)
(Fig 3
inset) by unaltered Ca2+ response between both
groups (Fig 2
inset), confirming our previous
findings.28

View larger version (28K):
[in this window]
[in a new window]
|
Figure 3. The time to reach the maximum Ca2+
response after PHA stimulation was not different between SVE patients
and control subjects. Data are mean±SEM (n=26). Inset, The time to
reach the maximum Ca2+ response after PHA stimulation was
significantly increased in lymphocytes from AD patients compared with
aged nondemented control subjects (ANOVA, P=.015, F=4.46).
Data are mean±SEM (n=26). **P<.01, post hoc Student's
t test.
|
|
As previously described,20 the Ca2+-amplifying
effect of ß-amyloid is not restricted to neuronal cells but could
likewise be demonstrated on the PHA-induced Ca2+ increase
in lymphocytes. Preincubation of freshly prepared lymphocytes obtained
from aged nondemented control subjects with the ß-amyloid fragment
25-35 (ßA25-35) (1 µmol/L) resulted in a significant
amplification (
Ca2+ ßA25-35: 13.4±9.4 nmol/L, the
difference between the Ca2+ response to PHA alone and the
Ca2+ response to PHA in the presence of ßA25-35) (Fig 4
). A similar amplification of the PHA-induced
Ca2+ increase was observed in lymphocytes from SVE patients
after exposure to ßA25-35 (
Ca2+ ßA25-35: 8.3±10.5
nmol/L) (Fig 4
). In contrast, ßA25-35 amplification was absent in
lymphocytes from AD patients (0.6±5.9 nmol/L; P<.001
compared with the
Ca2+ ßA25-35 values of the aged
control subjects, P<.01 compared with the
Ca2+ ßA25-35 values of the SVE patients) (Fig 4
inset,
Table
), confirming our previous findings about the marker function of
this effect in AD.22 30 31 The effect of ßA25-35 on
PHA-induced Ca2+ increase in lymphocytes was not different
between SVE patients taking calcium antagonists and calcium
antagonistfree individuals (
Ca2+
ßA25-35: 10.3±8.8 versus 7.2±11.4 nmol/L, respectively).
Furthermore, we investigated the effect of the potassium channel
blocker TEA on the PHA-induced Ca2+ increase in
lymphocytes. Preincubation of lymphocytes with TEA depolarizes the
membrane potential, which reduces the Ca2+ current into the
cell after PHA stimulation. Preincubation of cells with TEA (50
mmol/L) for 2 minutes caused a similar inhibition of the
Ca2+ increase in lymphocytes of nondemented control
subjects and SVE patients (51.9±9.9% inhibition versus 48.3±12.4%
inhibition, respectively) (Fig 5
). Lymphocytes of AD
patients, however, showed a tendency toward diminished effects of TEA
(42.2±14.6% inhibition) compared with nondemented control subjects
(Fig 5
inset), supporting the assumption of a pure AD-specific
potassium channel dysfunction.32 33 34

View larger version (31K):
[in this window]
[in a new window]
|
Figure 5. The inhibition of the PHA-induced Ca2+
increase after pretreatment with TEA (50 mmol/L, 2 minutes) was
not different in lymphocytes from aged control subjects (n=12) and SVE
patients (n=21). Data are mean±SEM. Inset, The percent inhibition was
slightly reduced in the AD group (n=14) compared with control subjects
(n=21). *P=.0662, Student's t test.
|
|
 |
Discussion
|
|---|
The present results clearly indicate that the Ca
2+
increase
after cell activation with the mitogen PHA is markedly reduced
in
lymphocytes from SVE patients compared with nondemented control
subjects.
Only very few data presently provide detailed information
about
specific changes of [Ca
2+]
i in patients
with cerebrovascular
disease or dementia. Two investigators studied
[Ca
2+]
i regulation
in lymphocytes of patients
with MID and compared them with aged
control subjects and AD
patients.
29 35 Consistent with our
data, neither
observed any difference in basal [Ca
2+]
i
levels
among the three groups. However, they did not observe
differences
after PHA stimulation in lymphocytes from MID patients
compared
with aged control subjects or AD patients. One explanation for
the
inconsistency of the results might be the higher PHA
concentrations
used by Adunsky et al
35 and Bondy et
al
29 (PHA 25 µg/mL
and 100 µg/mL), thereby
superimposing the possibly impaired
initial Ca
2+ release
from intracellular stores by intense Ca
2+ influx through
the plasma membrane into the cell during the
plateau phase of the
Ca
2+ response. Moreover, a different subgroup
of patients
was investigated in our study. The SVE patients
represent a
well-characterized group of patients with white
matter lesions
particularly in the frontal regions,
13 14 whereas
the
diagnosis of MID may represent a less precisely defined
group
of patients.
36 With respect to the
heterogeneity of our
findings in PHA-induced
Ca
2+ response in lymphocytes from SVE
patients compared
with other groups, the divergent type of subgroup
and the small number
of patients investigated by Adunsky et
al
35 (MID patients,
n=6) and by Bondy et al
29 (MID patients,
n=6) have to be
considered. The impaired PHA-induced Ca
2+ response
in
lymphocytes of SVE patients during the entire period of stimulation
seems
to be associated with a reduced Ca
2+ mobilization
from [Ca
2+]
i organelles, which mainly
dominates the initial Ca
2+ increase
after cell
activation,
25 whereas impaired Ca
2+ influx
mechanisms
seem to be involved in the delayed time of the maximum
Ca
2+ response in lymphocytes of AD
patients.
28
On the other hand, SVE patients could be distinguished from AD patients
in two experiments that appear to determine AD-specific alterations. In
agreement with our previous findings22 28 30 and those of
others,31 the lymphocyte sensitivity for the
Ca2+-amplifying effect of ß-amyloid is strongly reduced
in AD patients compared with nondemented control subjects and compared
with SVE patients. The specific reduction of the effect of ß-amyloid
on [Ca2+]i and even the complete absence of
the Ca2+-amplifying effect are striking and
represent an important peripheral marker of
AD.22 28 30 37
One possible explanation for the impaired ß-amyloid sensitivity of
lymphocytes in AD might be a potassium channel dysfunction, as
previously described by Etcheberrigaray et al32 33 from
skin fibroblasts of AD patients. The authors demonstrated that the
effect of ß-amyloid on potassium channel function and the subsequent
modulation of [Ca2+]i were reduced in skin
fibroblasts of AD patients as a result of the absence of TEA-sensitive
potassium channels in AD fibroblasts.33 A similar
reduction of the effects of TEA has been in lymphocytes from
AD.19 29 By blocking potassium channels, TEA is also able
to indirectly influence the Ca2+ influx into lymphocytes.
Preincubation of lymphocytes with TEA depolarizes the membrane
potential, which reduces the Ca2+ influx into the cell
after PHA stimulation.38 Consistent with our
data19 and those of others,29 lymphocytes
from AD patients showed a tendency to diminished effects of TEA
compared with control subjects. This mechanism was unaltered in
lymphocytes from SVE patients compared with control subjects.
Therefore, K+ channels appear not to be involved in the
impaired Ca2+ response of lymphocytes from SVE patients
after PHA stimulation. Whether this potassium channel alteration can be
linked to the reduced ß-amyloid sensitivity of AD lymphocytes is
currently under investigation.
In lymphocytes, an increase in [Ca2+]i
represents an early event in the intracellular signal cascade
of cell proliferation after PHA stimulation.12 Very
importantly, Tarkowski et al6 demonstrated that during
stroke the proliferative responses of T lymphocytes to the mitogens PHA
and concanavalin A were reduced compared with healthy control subjects.
Therefore, we can assume that findings of an impaired Ca2+
activation in SVE lymphocytes are in accordance with these data and
provide new insights into the pathogenesis of SVE with respect to a
probably altered immunologic function. The nervous system and the
immune system are known to communicate with soluble factors such as
cytokines and interact at various levels. The cytokines
are upregulated in patients with ischemic stroke and suggest an
early inflammatory response in human cerebrovascular
disease.7 8 Thus, modulators of cell-mediated immunity may
alter T lymphocyte and macrophage invasion or function, as seen
after vasospasm of superficial cerebral arteries and cerebral
injury.10 11 The cellular invasion characterized by the
alteration of the CD4+/CD8+ ratio in cerebral
tissues is seen in many forms of inflammation. Even in AD an increase
in CD8+ cytotoxic/suppressor T cells has been
found,39 probably initiating an activation of brain
microglia40 ; in addition, overexpression of two
cytokines may be involved in HIV neuropathogenesis with
similarities to the neuronal cell loss in AD.41
In conclusion, our results show that [Ca2+]i
regulation was specifically impaired after cell activation during SVE.
This effect was detected in circulating peripheral
lymphocytes obtained from these patients. There was some overlap
between the SVE and the AD groups. Several of the SVE patients showed
low responses to the Ca2+-amplifying effect of ß-amyloid
and after TEA treatment, as occurred in lymphocytes from AD patients.
When one considers the difficulties of differentiating between vascular
disease and the coexistence of vascular and degenerative
dementia,4 overlap of some results between patient groups
should be expected. Nonetheless, our work offers a new approach to
partially discriminate between two different groups of patients with
either cerebrovascular disease or AD.
 |
Selected Abbreviations and Acronyms
|
|---|
| ßA25-35 |
= |
ß-amyloid fragment 25-35 |
| AD |
= |
Alzheimer's disease |
| ADRDA |
= |
Alzheimer's Disease and Related Disorders Association |
| AIREN |
= |
Association Internationale pour la Recherche et l'Enseignement en
Neurosciences |
| MID |
= |
multi-infarct dementia |
| NIN(C)DS |
= |
National Institute of Neurological (and Communicative) Disorders and
Stroke |
| PHA |
= |
phytohemagglutinin |
| SVE |
= |
subcortical vascular encephalopathy |
| TEA |
= |
tetraethylammonium chloride |
|
 |
Acknowledgments
|
|---|
This study was supported by grants from the Deutsche
Forschungsgemeinschaft,
SFB 258, projects K2 and K5, and the
Forschungsfond Fakultät
Mannheim.
Received February 5, 1997;
revision received April 21, 1997;
accepted April 21, 1997.
 |
References
|
|---|
-
Roman GC. The
epidemiology of vascular dementia. In: Hartmann
A, Kuschinsky W, Hoyer S, eds. Cerebral Ischaemia and
Dementia. Berlin, Germany: Springer-Verlag; 1991:9-15.
-
Meyer JS, Judd W, Judd MS, Tawakina T, Rogers RL,
Mortel K. Improved cognition after control of risk factors for
multi-infarct dementia. JAMA. 1986;256:2203-2209.[Abstract]
-
Rosen WG, Terry RD, Fuld P, Katzmann R, Peck A.
Pathological verification of ischemic score in differentiation
of dementia. Ann Neurol. 1979;7:486-488.
-
Amar K, Wilcock GK, Scott M. The diagnosis of
vascular dementia in the light of new criteria. Age
Ageing. 1996;25:51-56.[Abstract/Free Full Text]
-
Tarkowski E, Ekelund P, Tarkowski A. Increased
systemic T lymphocyte reactivity in patients with established
stroke. J Clin Lab Immunol. 1991;35:171-176.[Medline]
[Order article via Infotrieve]
-
Tarkowski E, Naver H, Wallin BG, Blomstrand C,
Tarkowski A. Lateralization of T-lymphocyte responses in
patients with stroke. Stroke. 1995;26:57-62.[Abstract/Free Full Text]
-
Elneihoum AM, Falke P, Axelsson L, Lundberg E,
Lindgräde F, Ohlsson K. Leukocyte activation detected by
increased plasma levels of inflammatory mediators in patients with
ischemic cerebrovascular diseases. Stroke. 1996;27:1734-1738.[Abstract/Free Full Text]
-
Tomimoto H, Akiguchi I, Wakita H, Kinoshita A, Ikemoto
A, Nakamura S, Kimura J. Glial expression of cytokines
in the brains of cerebrovascular patients. Acta
Neuropathol. 1996;92:281-287.[Medline]
[Order article via Infotrieve]
-
Kubota T, Handa Y, Tsuchida A, Kaneko M, Kobayashi H,
Kubota T. The kinetics of lymphocyte subsets and
macrophages in subarachnoid space after
subarachnoid hemorrhage in rats.
Stroke. 1993;24:1993-2001.[Abstract/Free Full Text]
-
Jander S, Kraemer M, Schroeter M, Witte OW, Stoll
G. Lymphocytic infiltration and expression of intercellular
adhesion molecule-1 in photochemically induced ischemia of the
rat cortex. J Cereb Blood Flow Metab. 1995;15:42-51.[Medline]
[Order article via Infotrieve]
-
Akopov SE, Simonian NA, Grigorian GS. Dynamics
of polymorphonuclear leukocyte accumulation in acute cerebral
infarction and their correlation with brain tissue damage.
Stroke. 1996;27:1739-1743.[Abstract/Free Full Text]
-
Gelfand WE. The ionic and biochemical basis for
T-cell activation and proliferation. Clin Immunol
Immunopathol. 1991;61:S1-S9.
-
Hennerici M, Oster M, Cohen SA, Schwartz A, Motsch
L, Daffertshofer M. Are gait disturbances and white
matter lesions early indicators of vascular dementia?
Dementia. 1994;3:197-202.
-
Schreiner A, Pohlmann-Eden B, Schwartz A, Hennerici
M. Epileptic seizures in subcortical vascular
encephalopathy. J Neurol Sci. 1995;130:171-177.[Medline]
[Order article via Infotrieve]
-
Lang EW, Daffertshofer M, Daffertshofer A, Wirth SB,
Hennerici M. Variability of vascular territory in
stroke. Stroke. 1995; 26:942-945.
-
Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL,
Masdeu JC, Garcia JH, Amaducci L, Orgogozo J-M, Brun A, Hofman A, Moody
DM, O'Brien MD, Yamaguchi T, Grafman J, Drayer BP, Bennett DA, Fisher
M, Ogata J, Kokmen E, Bermejo F, Wolf PA, Gorelick PB, Bick KL, Pajeau
AK, Bell MA, DeCarli C, Culebras A, Korczyn A, Bogousslavsky J,
Hartmann A, Scheinberg P. Vascular dementia:
diagnostic criteria for research studies: report of the
NINDS-AIREN International Workshop. Neurology. 1993;43:250-260.[Abstract/Free Full Text]
-
McKhann G, Drachman D, Folstein M, Katzman R, Price D,
Stadlan EM. Clinical diagnosis of Alzheimer's disease:
a report of the NINCDS-ADRDA work group under the auspices of the
Department of Health and Human Services Task Force on
Alzheimer's Disease. Neurology. 1984;34:939-944.[Abstract/Free Full Text]
-
Förstl H, Besthorn C, Geiger-Kabisch C, Sattel H,
Schreiter-Gasser U. Psychotic features and the course of
Alzheimer's disease: relationship to cognitive, EEG and
CT-scan findings. Acta Psychiatr Scand. 1993;87:395-399.[Medline]
[Order article via Infotrieve]
-
Lewis RS, Cahalan MD. Potassium and calcium
channels in lymphocytes. Ann Rev Immunol. 1995;13:623-653.[Medline]
[Order article via Infotrieve]
-
Eckert A, Hartmann H, Müller WE. ß-Amyloid
protein enhances the mitogen-induced calcium response in circulating
human lymphocytes. FEBS Lett. 1993;330:49-52.[Medline]
[Order article via Infotrieve]
-
Boyum A. Separation of lymphocytes, granulocytes
and monocytes from human blood using iodinated density
gradient media. Methods Enzymol. 1984;108:88-102.[Medline]
[Order article via Infotrieve]
-
Eckert A, Förstl H, Hartmann H, Czech C,
Mönning U, Beyreuther K, Müller WE. The amplifying
effect of ß-amyloid on cellular calcium signalling is reduced in
Alzheimer's disease. Neuroreport. 1995;6:1199-1202.[Medline]
[Order article via Infotrieve]
-
Grynkiewicz G, Poenie M, Tsien RY. A new
generation of Ca2+ indicators with greatly improved
fluorescence properties. J Biol Chem. 1985;260:3440-3450.[Abstract/Free Full Text]
-
Eckert A, Förstl H, Zerfass R, Hartmann H,
Müller WE. Lymphocytes and neutrophils as
peripheral models to study the effect of ß-amyloid
on cellular calcium signalling in Alzheimer's disease.
Life Sci. 1996;59:499-510.[Medline]
[Order article via Infotrieve]
-
Zweifach A, Lewis RS. Mitogen-regulated
Ca2+ current of T lymphocytes is activated by
depletion of intracellular Ca2+ stores. Proc
Natl Acad Sci U S A. 1993;90:6295-6299.[Abstract/Free Full Text]
-
Eckert A, Hartmann H, Förstl H, Müller
WE. Alterations of intracellular calcium regulation during aging
and Alzheimer's disease in nonneuronal cells.
Life Sci. 1994;55:2019-2029.[Medline]
[Order article via Infotrieve]
-
Hartmann H, Eckert A, Förstl H, Müller
WE. Similar age-related changes of free intracellular calcium in
lymphocytes and central neurons: effects of Alzheimer's
disease. Eur Arch Psychiatry Clin Neurosci. 1994;243:218-223.[Medline]
[Order article via Infotrieve]
-
Eckert A, Förstl H, Zerfass R, Hennerici M,
Müller WE. Free intracellular calcium in
peripheral cells in Alzheimer's disease.
Neurobiol Aging. In press.
-
Bondy B, Klages U, Müller-Spahn F, Hock C.
Cytosolic free [Ca2+]i in mononuclear
blood cells from demented patients and healthy controls.
Eur Arch Psychiatry Clin Neurosci. 1994;243:224-228.[Medline]
[Order article via Infotrieve]
-
Eckert A, Förstl H, Hartmann H, Müller
WE. Decreased ß-amyloid sensitivity in
Alzheimer's disease. Lancet. 1993;
342:805-806.
-
Bondy B, Hofmann M, Müller-Spahn F, Witzko M,
Hock C. Reduced ß-amyloid response in lymphocytes of
patients with Alzheimer's disease.
Pharmacopsychiatry.. 1995;28:143-146.[Medline]
[Order article via Infotrieve]
-
Etcheberrigaray R, Ito E, Oka K, Tofel-Grehl B, Gibson
GE, Alkon DL. Potassium channel dysfunction in fibroblasts
identifies patients with Alzheimer's disease. Proc Natl
Acad Sci U S A. 1993;90:8209-8213.[Abstract/Free Full Text]
-
Etcheberrigaray R, Ito E, Kim CS, Alkon DL.
Soluble ß-amyloid induction of Alzheimer's
phenotype for human fibroblast K+ channels.
Science. 1994;264:276-279.[Abstract/Free Full Text]
-
Bondy B, Hofmann M, Müller-Spahn F, Witzko M,
Hock C. The PHA-induced calcium signal in lymphocytes is altered
after blockade of K+-channels in Alzheimer's
disease. J Psychiatr Res. 1996;30:217-227.[Medline]
[Order article via Infotrieve]
-
Adunsky A, Baram D, Hershkowitz M, Mekori YA.
Increased cytosolic calcium in lymphocytes of Alzheimer
patients. J Neuroimmunol. 1991;33:167-172.[Medline]
[Order article via Infotrieve]
-
Gottfries CG, Blennow K, Karlsson L, Wallin A.
The neurochemistry of vascular dementia. Dementia. 1994;5:163-167.
-
Müller WE, Hartmann H, Eckert A, Velbinger K,
Förstl H. Free intracellular calcium in aging and
Alzheimer's disease. Ann N Y Acad Sci. 1996;786:305-320.[Abstract]
-
Gelfand EW, Cheung RK, Grinstein S. Role of
membrane potential in the regulation of lectin-induced calcium
uptake. J Cell Physiol. 1984;121:533-539.[Medline]
[Order article via Infotrieve]
-
Dickson DW, Rogers J. Neuroimmunology of
Alzheimer's disease: a conference report.
Neurobiol Aging. 1992;13:793-798.[Medline]
[Order article via Infotrieve]
-
Hartwig M. Immune ageing and
Alzheimer's disease. Neuroreport. 1995;6:1274-1276.[Medline]
[Order article via Infotrieve]
-
Stanley LC, Mrak RE, Woody RC, Perrot LJ, Zthang S,
Marshak DR, Nelson SJ, Griffin WS. Glial cytokines as
neuropathogenic factors in HIV infection: pathogenic similarities to
Alzheimer's disease. J Neuropathol Exp
Neurol. 1994;53:231-238.[Medline]
[Order article via Infotrieve]
This article has been cited by other articles:

|
 |

|
 |
 
K. Fassbender, T. Bertsch, O. Mielke, F. Muhlhauser, and M. Hennerici
Adhesion Molecules in Cerebrovascular Diseases : Evidence for an Inflammatory Endothelial Activation in Cerebral Large- and Small-Vessel Disease
Stroke,
August 1, 1999;
30(8):
1647 - 1650.
[Abstract]
[Full Text]
[PDF]
|
 |
|